ERBB2 and ovarian cancer: Therefore the greater effectiveness and enhanced cytotoxic action of the combination of the HER2 targeted immunotherapeutic agents may be at least partially explained by their unique ability to cause transcriptional inhibition of NRF2 and greater repression of its antioxidant function in low, moderate and high HER2 expressing ovarian cancer cell lines.